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Background: Many topical agents have been used for promotion of healing of chronic venous ulcers. One
such agent that has been tried is phenytoin. The effect of phenytoin on cutaneous healing has been
suggested. This study was designed to evaluate the efﬁcacy of topical phenytoin in healing of venous
ulcerations.
Methods: One hundred and four patients with chronic venous ulcers were recruited in this study. They
were divided into study group and control group. The study group was 54 patients while control group
was 50 patients. Patients in the study group were subjected to dressing of their ulcers with topical
phenytoin once daily while patients in the control group were subjected to dressing with normal saline.
All patients were followed up for eight weeks and assessed for their ulcer status and recorded as:
complete healing, partial healing, no improvement or worsening of the condition.
Results: By the end of the eight weeks, complete healing was evident in 35/54 of the patients (64.8%) in
the study group and 26/50 of the patients (52%) in the control group. It was statistically signiﬁcant
(p¼ .04). The rate of reduction in the mean surface area of the ulcers was faster in the study group than
control group. Minor side effects were reported among 4 patients (7.4%) of the study group in the form of
burning sensation.
Conclusion: Topical phenytoin can be used to enhance healing of chronic venous ulcers in conjunction
with the established treatment. It has favorable results and tolerable local side effects.
 2011 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Venous Leg ulcers are common and are associated with signif-
icant morbidity, temporary or permanent disability and high cost of
healthcare. The two main causes are primary varicose veins and
late effects of deep venous thrombosis (post-thrombotic or post-
phlebitic syndrome). It results from impaired tissue nutritionwhich
causes skin irritation and subsequent stasis dermatitis. It is char-
acterized by the presence of thin, shinny, brownish and desqumi-
native skin that lacks the support of the underlying subcutaneous
tissues.1,2
Many preventive and therapeutic approaches have been tried to
manage venous ulcerations and new trials are still evolving.3 In the
recent years many researches tried to ﬁnd out the new concern for
such a problem in the form of compression bandage, wound care
and surgery aiming to reduce the venous hypertension.4,5
A plethora of topical preparations are now available under the
rubric of wound care materials. The choice of agents can beile), þ20 64 3381302 (work),
scuegypt.edu.eg (E.Hokkam).
Elsevier Ltd on behalf of Surgical Abewildering.6 One such agent has been tried is phenytoin.
Phenytoin (Diphenylhydantoin or Dilantin) was introduced into
therapy about 70 years ago for effective control of convulsive
disorders.7 In 1958, a clinical study demonstrated that phenytoin
sodium accelerates gingival wound healing compared with con-
trols.8 Since that time, phenytoin has been used in the healing of
a diversity of wounds.9e13
The ﬁrst double-blind, placebo-controlled clinical study
involving theuseof phenytoin in legulcersdemonstrated that,when
compared with controls, the use of phenytoin promoted wound
healing.14
A number of subsequent studies have been conducted to assess
theeffectofphenytoinon thehealingof avarietyofwounds including
diabetic foot ulcers,15,16 trophic ulcers in leprosy,17,18 chronic leg
ulcers,19,20 pressure ulcers,21 superﬁcial burn wounds22 and trau-
matic wounds.23 Recently, Shaw et al.24 published a systematic
review identifying, summarizing and critically appraising the clinical
evidence regarding the effects of phenytoin onwound healing.
Used topically, phenytoin appears to enhance healing without
side effects. Its wound-related pharmacology has been investi-
gated.25 Phenytoin increases gene expression of the platelet-
derived growth factor B chain in macrophages and monocytes.26ssociates Ltd.
Table 1
Base line characteristics of studied patients.
Characteristic Study group
(n¼ 54)
Control group
(n¼ 50)
Age (years) 47.3 6.4 45.9 3.8
Duration of ulcer (weeks) 3.1 1.3 3.9 1.0
Size of ulcer (cm2) 5.7 2.8 6.1 3.1
Sex
Male 21 (38.9%) 21 (42%)
Female 33 (61.1%) 29 (58%)
Job
Housewife 13 (24.1%) 10 (20%)
Teacher 17 (31.5%) 15 (30%)
Worker 11 (20.4%) 9 (18%)
Employee 10 (18.5%) 9 (18%)
Retired 3 (5.6%) 7(14%)
Onset
Non-recurrent 39 (72.2%) 34 (68%)
Recurrent 15 (27.8%) 16 (32%)
Aetiology
Varicose veins 24 (44.4%) 21 (42%)
Post-thrombotic 30 (55.6%) 29 (58%)
Percent of change ¼ ðPretreatment surface area final surface areaÞ=Pretreatment surface area 100:
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with conventional saline dressings.27 It may promote wound
healing through multiple mechanisms, including stimulation of
ﬁbroblast proliferation, facilitation of collagen deposition, gluco-
corticoid antagonism and antibacterial activity.28
The effect of topical administration of phenytoin for the
promotion of healing was investigated in diverse types of chronic
wounds. The present study focuses on its effect on chronic venous
ulcers.
2. Patients and methods
The study was carried out as randomized controlled trial on the speciﬁc base
line. After approval of our ethics committee, 104 patients with chronic venous leg
ulcer were recruited from the outpatient clinic of surgery, Suez Canal University
Hospital, Ismailia, Egypt. They were divided into study group and control group
using coin ﬂipping technique. The study group consisted of ﬁfty four patients while
control group consisted of ﬁfty patients. Patients were excluded from the study in
cases of allergy to phenytoin, marjolin’s ulcers, ulcers with infected gangrene and
patients with multiple ulcers. Patients with infected ulcers have the chance to be
included in the study once their ulcers become clean and has healthy granulation
tissue. Patients who experienced previous surgical intervention should wait at least
6 months after the operation to assure that surgery will not contribute in ulcer
healing.Fig. 1. A case of comAll of the studied patients were subjected to complete medical history stressing
on any chronic medical illness, duration of the ulcer and any previous surgical
intervention (saphenous vein stripping). Detailed general and local examinations
were performed for all patients. Doppler studies were done for evaluation of the
venous system of the leg containing the ulcer. All patients were treated systemi-
cally in the form of oral phlebotropic drugs (Diosmin) and compression bandage.
Beside that they were advised to avoid prolonged standing and elevate their legs
whenever possible.
Patients in the study group were subjected to dressing of their ulcers with
topical phenytoin while patients in the control group were subjected to dressing
with placebo (normal saline). Phenytoin is prepared in a lotion form through adding
1 g of it to 25 ml of liposomal base and shook well before application.
In all patients, the ulcer was cleaned and washed with normal saline, then dried
with sterile gauze and ﬁnally, the limb was wrapped by crepe bandage. In control
group, this was enough while in the study group; a thin layer of phenytoin was
applied to the surface area of the ulcer before covering it with a gauze dressing. The
patient was asked to dress his/her ulcer daily using the previous technique and come
to the outpatient clinic every week for follow up. The patient was instructed to avoid
prolonged standing and to keep his/her leg elevated as much as he/she can.
The ulcer status was assessed every week and at the end of the eight weeks the
ulcer’s condition was evaluated as complete healing, partial healing, no improve-
ment and worsening. To measure ulcer surface area, the ulcer borders were traced
on to a paper overlay. This primary schematic representation was then scanned,
redrawn and measured by AutoCAD 2000 software.
The percentage of change in ulcer surface area was calculated asAnalysis of variance (ANOVA) test and t-test were used for testing signiﬁcance of
the difference between quantitative variables while Chi square test was used for
qualitative variables. A probability value (p-value) less than 0.05 was considered
statistically signiﬁcant.
3. Results
The study was conducted among 104 patients with chronic
venous ulcer. The mean age of patients in the study group was
estimated to be 47.3 6.4 years while it was 45.9 3.8 in the
control group. All patients were in age group ranging from 24 to 69
years. Females were more commonly affected than males in both
groups (61.1% in the study group vs. 58% in the control group). Most
of the ulcers were non-recurrent in both groups. The recurrent
ulcers have an average 1.2 time of recurrence. In the study group,
the mean duration of the ulcer was 3.1 weeks with mean size
estimated to be 5.7 cm2 while the main durationwas 3.9 weeks and
the main size was 6.1 cm2 in the control group. Most of the studied
patients were teachers and housewives followed by workers and
employees. On the basis of clinical and duplex assessment, the
ulcers were secondary to varicose veins in 24 patients (44.4%) and
21 patients (42%) in the study group and control group respectivelyplete healing.
Table 2
Ulcer status at the end of the treatment period.
Ulcer status Study group (n¼ 54) Control group (n¼ 50)
Complete healing 35 (64.8%) 26 (52%)
Partial healing 11 (20.4%) 18 (36%)
No improvement 6 (11.1%) 4 (8%)
Worsening 2 (3.7%) 2 (4%)
Fig. 2. The rate of reduction in the mean surface area of the ulcers in both groups.
E. Hokkam et al. / International Journal of Surgery 9 (2011) 335e338 337
ORIGINAL RESEARCHwhile theywere post-thrombotic in 30 patients (55.6%) of the study
group and 29 patients (58%) of the control group (Table 1).
At the end of the treatment period (eight weeks), complete
healing was evident in thirty ﬁve patients (64.8%) of the study
group and twenty six patients (52%) in control group. It was
statistically signiﬁcant (p¼ .04). Patients who showed partial
healing, no improvement or worsening of their ulcer were 11
patients (20.4%), 6 patients (11.1%) and two patients (3.7%)
respectively in the study group vs 18 patients (36%), 4 patients (8%)
and two patients (4%) in the control group (Fig. 1). Table 2 showed
the ulcer status of all patients in both groups by the end of the
treatment period.
Twenty four patients of the study group (44.4%) have been
exposed to previous surgical treatment in the form of saphenous
vein stripping and forty patients (74.1%) used other topical treat-
ments for the current ulcer. In the control group; twenty one
patients (42%) has previous surgical treatment and thirty ﬁve
patients (70%) used previous topical treatments. There were no
reported signiﬁcant side effects between both groups except for the
presence of burning sensation in 4 patients (7.4%) in the study
group (p¼ .042) (Table 3)
The rate of reduction in the mean surface area of the ulcers was
faster in the study group than control group. This was more evident
starting from the third week of follow up till the end of the treat-
ment period (Fig. 2).
4. Discussion
Venous ulcers are not a new problem, since they arewell known
to have plagued humankind since ancient times. The ﬁrst written
description of treatment of probable venous ulcers was found in the
Papyrus of Eber originating from Egypt around 1550 bc.29 Nowa-
days, many types of wound dressings and topical agents are now
novel therapeutic options that may be used in addition to the “gold
standard,” compression therapy.30
The capacity of diphenylhydantoin sodium (phenytoin) e as
a topical agente to accelerate ulcer healing was reportedmore than
40 years ago. Since then, it has been used topically for different
kinds of wounds and ulcers such as war wounds, atrophic ulcers,
leg ulcers and burns, and positive effects have been reported.12,31
Althoughmany previous studies evaluated the efﬁcacy of topical
phenytoin in the treatment of chronic leg ulcers, none of them
specify venous ulcer in particular. To our knowledge; the current
study is the ﬁrst to assess topical phenytoin in the management of
chronic venous ulcers.
In the present study, the age of the patients with chronic venous
ulcers ranged between 24 and 69 years; which is slightly lower
than that observed by Lyon et al.32 who reported age rangeTable 3
Previous surgical and topical treatment and side effects in both groups.
Variable Study group (n¼ 54) Control group (n¼ 50)
Previous surgical treatment 24 (44.4%) 21 (42%)
Previous topical treatment 40 (74.1%) 35 (70%)
Side effects 4 (7.4%) 0 (0%)between 25 and 89 years. The young mean age of the patients is
reported in other Egyptian studies33,34; however, female predom-
inance was evident only in the present study.
Simpson et al.14 was the ﬁrst to study the effect of phenytoin in
chronic leg ulcers. They used oral phenytoin sodium to treat 28
patients in a double-blind, placebo-controlled trial. They reported
decrease in the mean-wound area in the treatment group than the
control group. Although our results match with that of Simpson’
team,14 we strongly disagree with them in their administration
route. We prefer the direct application of the drug instead of the
oral route as they used. Topical application of phenytoin, results in
direct access of the drug to the target site without undergoing
classical metabolic pathways, and there is no risk of causing
systemic side effects which is seenwith the oral therapy for wound
healing.25
Consistent with our results Pendse et al.,27 evaluated the
effectiveness of topical phenytoin in treatment of chronic skin
ulcers. Seventy-ﬁve inpatients with chronic skin ulcers were
included in their controlled trial. Forty patients were treated with
topical phenytoin, and 35 patients with conventional saline
dressings. Assessment of the wounds included wound area,
bacteriologic cultures and clinical assessment. At the end of the
study, 29 of 40 phenytoin-treated ulcers had healed completely
versus 10 of 35 controls.
In the present study, the overall complete healing among
patients in phenytoin group was 64.8% which is lower than that
reported by Pendse et al.27 (72.5%) and higher than that reported by
Oluwatosin et al.19 (24%).
The present study showed faster reduction of the mean surface
area of the ulcers in phenytoin group. The same happened with
Carneiro and Nyawawa,20 who compared topical phenytoin with
Edinburgh University solution of lime (EUSOL) in terms of rate of
ulcer healing, analgesic and antibacterial properties in non-malig-
nant chronic leg ulcers.
Side effects of topical phenytoin include transient burning
sensation when it is ﬁrst applied to a wound 35 and hypertrophic
granulation tissue formation.15,27 The latter was found to be avo-
idable by ceasing therapy once granulation tissue covers the total
wound area.14 This is consistent with our results as we did not
report signiﬁcant side effects in the study group except for burning
sensation in 4 patients (7.4%).
In conclusion; topical phenytoin is an inexpensive and easy to
use topical agent. It may improve ulcer healing but should be used
in conjunctionwith the standard management for venous leg ulcer.
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